The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
Open accessAbstract
T cell immunotherapy is emerging as a powerful strategy to treat cancer and may improve outcomes for patients with glioblastoma (GBM). We have developed a chimeric antigen receptor (CAR) T cell immunotherapy targeting IL-13 receptor α2 (IL13Rα2) for the treatment of GBM. Here, we describe the optimization of IL13Rα2-targeted CAR T cells, including the design of a 4-1BB (CD137) co-stimulatory CAR (IL13BBζ) and a manufacturing platform using enriched central memory T cells. Utilizing orthotopic human GBM models with patient-derived tumor sphere lines in NSG mice, we found that IL13BBζ-CAR T cells improved anti-tumor activity and T cell persistence as compared to first-generation IL13ζ-CAR CD8 + T cells that had shown evidence for bioactivity in patients. Investigating the impact of corticosteroids, given their frequent use in the clinical management of GBM, we demonstrate that low-dose dexamethasone does not diminish CAR T cell anti-tumor activity in vivo. Furthermore, we found that local intracranial delivery of CAR T cells elicits superior anti-tumor efficacy as compared to intravenous administration, with intraventricular infusions exhibiting possible benefit over intracranial tumor infusions in a multifocal disease model. Overall, these findings help define parameters for the clinical translation of CAR T cell therapy for the treatment of brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Self-citationDolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 824
Donnelly, M. L. L., Luke, G., Mehrotra, A., Li, X., Hughes, L. E., Gani, D., & Ryan, M. D. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-5-1013 · Cited by 798
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Self-citationTandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572
The pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
The blood-brain barrier and immune function and dysfunction
Banks, W. A., & Erickson, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.031 · Cited by 523
Trafficking of T Cells into Tumors
Slaney, C. Y., Kershaw, M. H., & Darcy, P. K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2458 · Cited by 410
Kahlon, K. S., Brown, C., Cooper, L. J. N., Raubitschek, A., Forman, S. J., & Jensen, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0454 · Cited by 368
Self-citationNoninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma
Yaghoubi, S. S., Jensen, M. C., Satyamurthy, N., Budhiraja, S., Paik, D., Czernin, J., & Gambhir, S. S. (2009) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1278 · Cited by 366
Corticosteroids in brain cancer patients: benefits and pitfalls
Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.1 · Cited by 361
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Keu, K. V., Witney, T. H., Yaghoubi, S., Rosenberg, J., Kurien, A., Magnusson, R., Williams, J., Habte, F., Wagner, J. R., Forman, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2196 · Cited by 319
Self-citationGraef, P., Buchholz, V. R., Stemberger, C., Flossdorf, M., Henkel, L., Schiemann, M., Drexler, I., Höfer, T., Riddell, S. R., & Busch, D. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.018 · Cited by 311
Novel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 260
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R., & Gillespie, G. Y. (1999) · PubMed · Cited by 254
Costimulation of T cells by OX40, 4-1BB, and CD27
Croft, M. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00025-x · Cited by 231
Brown, C. E., Starr, R., Aguilar, B., Shami, A. F., Martinez, C., D'Apuzzo, M., Barish, M. E., Forman, S. J., & Jensen, M. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1669 · Cited by 225
Self-citationAnti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
Abramson, J. S., McGree, B., Noyes, S., Plummer, S., Wong, C., Chen, Y.-B., Palmer, E., Albertson, T., Ferry, J. A., & Arrillaga-Romany, I. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1704610 · Cited by 206
Jonnalagadda, M., Mardiros, A., Urak, R., Wang, X., Hoffman, L. J., Bernanke, A., Chang, W.-C., Bretzlaff, W., Starr, R., Priceman, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.208 · Cited by 204
Self-citationSuccessful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy
Hong, J. J., Rosenberg, S. A., Dudley, M. E., Yang, J. C., White, D. E., Butman, J. A., & Sherry, R. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1507 · Cited by 191
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
Katz, S. C., Point, G. R., Cunetta, M., Thorn, M., Guha, P., Espat, N. J., Boutros, C., Hanna, N., & Junghans, R. P. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.14 · Cited by 177
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy
Thaci, B., Brown, C. E., Binello, E., Werbaneth, K., Sampath, P., & Sengupta, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou045 · Cited by 168
Self-citationGlioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis
Brown, C. E., Warden, C. D., Starr, R., Deng, X., Badie, B., Yuan, Y.-C., Forman, S. J., & Barish, M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077769 · Cited by 166
Self-citationEngraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice
Wang, X., Berger, C., Wong, C. W., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2010-10-310599 · Cited by 159
Self-citationBrown, C. E., Vishwanath, R. P., Aguilar, B., Starr, R., Najbauer, J., Aboody, K. S., & Jensen, M. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3332 · Cited by 153
Self-citationImmune Reactivity in the Nervous System: Modulation of T-lymphocyte Activation By Glial Cells
Wekerle, H., Sun, D., Oropeza-Wekerle, R. L., & Meyermann, R. (1987) · Journal of Experimental Biology · doi:10.1242/jeb.132.1.43 · Cited by 147
Wang, X., Naranjo, A., Brown, C. E., Bautista, C., Wong, C. W., Chang, W.-C., Aguilar, B., Ostberg, J. R., Riddell, S. R., Forman, S. J., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318270dec7 · Cited by 140
Self-citationJarboe, J. S., Johnson, K. R., Choi, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1493 · Cited by 139
Kong, S., Sengupta, S., Tyler, B., Bais, A. J., Ma, Q., Doucette, S., Zhou, J., Sahin, A., Carter, B. S., Brem, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0319 · Cited by 134
Ramos, C. A., Savoldo, B., & Dotti, G. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000031 · Cited by 106
Riccardi, C., Cifone, M. G., & Migliorati, G. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400609 · Cited by 100
Krenciute, G., Krebs, S. S., Torres, D., Wu, M.-F., Liu, H., Dotti, G., Li, X., Lesniak, M. S., Balyasnikova, I. V., & Gottschalk, S. M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.199 · Cited by 90
Krebs, S. S., Chow, K. K. H., Yi, Z., Rodríguez-Cruz, T., Hegde, M. G., Gerken, C. P., Ahmed, N. M., & Gottschalk, S. M. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.02.012 · Cited by 83
Morrison, B. E., Marcondes, M. C. G., Nomura, D. K., Sánchez-Alavez, M., Sánchez-González, A., Saar, I., Kim, K., Bartfai, T., Maher, P. A., Sugama, S., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102150 · Cited by 79
IL-13 receptor isoforms: Breaking through the complexity
Tabata, Y., & Hershey, G. K. K. (2007) · Current Allergy and Asthma Reports · doi:10.1007/s11882-007-0051-x · Cited by 71
Ahmed, N. M., Brawley, V. S., Hegde, M. G., Bielamowicz, K., Wakefield, A., Ghazi, A., Ashoori, A., Diouf, O., Gerken, C. P., Landi, D. B., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o11 · Cited by 62
Standard of care therapy for malignant glioma and its effect on tumor and stromal cells
Jones, T. S., & Holland, E. C. (2011) · Oncogene · doi:10.1038/onc.2011.398 · Cited by 52
CD19 CAR Therapy for Acute Lymphoblastic Leukemia
Sadelain, M., Brentjens, R. J., Rivière, I., & Park, J. H. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e360 · Cited by 51
O’Rourke, D. M., Nasrallah, M. P., Morrissette, J. J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2067 · Cited by 33
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,792
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Metadata
- Authors
- Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., Ostberg, J. R., D’Apuzzo, M., Badie, B., Barish, M. E., & Forman, S. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 26
- Issue
- 1
- Pages
- 31-44
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2766649683
- Cited by
- 299
- References
- 48
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.